Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $40 price target on Heron Therapeutics (NASDAQ: HRTX) announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Heron Therapeutics (HRTX) PT Raised to $66 at Needham & CompanyJune 21, 2018 3:48 PM Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ OpportunityJune 21, 2018 1:15 PM Heron Therapeutics (HRTX) PT Raised to $51 at JefferiesJune 21, 2018 11:39 AM Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISIJune 21, 2018 10:23 AM Pre-Open Movers 06/21: (CASI) (HRTX) (DRI) (KR) Higher; (VERI) (LMNR) (AOBC) Lower (more...)June 21, 2018 9:27 AM Form 8-K HERON THERAPEUTICS, INC. For: Jun 21June 21, 2018 8:12 AM Heron Therapeutics (HRTX) Says HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDAJune 21, 2018 8:05 AM HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDAJune 21, 2018 8:05 AM Heron Therapeutics (HRTX) Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation Achieves Primary EndpointsJune 21, 2018 8:01 AM Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast AugmentationJune 21, 2018 8:00 AM